Vaxcyte Announces Board Changes and Executive Compensation Updates
Ticker: PCVX · Form: 8-K · Filed: May 1, 2025 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 8-K |
| Filed Date | May 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: PCVX
TL;DR
Vaxcyte's board is shuffling with a director out and a new one in; exec pay details also released.
AI Summary
On May 1, 2025, Vaxcyte, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announced the departure of Director George J. Incledon and the appointment of Dr. Sarah E. Fortune as a new director. Additionally, the company provided updates on the compensatory arrangements for its named executive officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance and executive compensation matters, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Vaxcyte, Inc. (company) — Registrant
- George J. Incledon (person) — Departing Director
- Dr. Sarah E. Fortune (person) — Appointed Director
- May 1, 2025 (date) — Date of Report
FAQ
Who departed from Vaxcyte's board of directors?
George J. Incledon departed from Vaxcyte's board of directors.
Who was appointed as a new director at Vaxcyte?
Dr. Sarah E. Fortune was appointed as a new director at Vaxcyte.
What is the exact date of this 8-K filing?
The exact date of this 8-K filing is May 1, 2025.
What is Vaxcyte's principal executive office address?
Vaxcyte's principal executive office is located at 825 Industrial Road, Suite 300, San Carlos, California 94070.
What is the IRS Employer Identification Number for Vaxcyte, Inc.?
The IRS Employer Identification Number for Vaxcyte, Inc. is 46-4233385.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 by George J. Incledon regarding Vaxcyte, Inc. (PCVX).